2021, Número 4
<< Anterior Siguiente >>
Medicina & Laboratorio 2021; 25 (4)
Histiocitosis de células de Langerhans, una afección pulmonar infradiagnosticada en fumadores: reporte de caso y revisión de la literatura
Cabrera-Rojas DL, Gómez-Correa GA, Varela-Aguirre GJ
Idioma: Español
Referencias bibliográficas: 60
Paginas: 721-734
Archivo PDF: 299.60 Kb.
RESUMEN
La histiocitosis de células de Langerhans (HCL) es una enfermedad que
puede afectar a pacientes de cualquier edad, siendo en adultos un trastorno poco
común de etiología desconocida, que ocurre predominantemente en fumadores
jóvenes, sin diferencias en género. Aunque ciertas particularidades de la enfermedad
pueden compartirse con las manifestaciones presentes en la población
pediátrica, la proporción de casos con afectación pulmonar es mucho mayor en
adultos. A menudo evoluciona a través de brotes sucesivos y su gravedad varía
desde formas benignas hasta potencialmente mortales. Algunos pacientes desarrollan
un importante deterioro funcional con repercusión psicosocial, que impacta
en la calidad de vida y se asocia a discapacidad prolongada. La clave diagnóstica
estará determinada por el antecedente de tabaquismo, la presencia de nódulos,
nódulos cavitados y quistes de paredes gruesas y delgadas en la tomografía
computarizada de tórax de alta resolución (TACAR). Sin embargo, el diagnóstico
definitivo requiere la identificación de granulomas de células de Langerhans, que
generalmente se logra mediante la realización de una biopsia pulmonar y su estudio
histopatológico e inmunohistoquímico. En la actualidad, podríamos considerar
a esta entidad como una enfermedad huérfana, de la cual aún no se tiene claridad
del mecanismo patogénico, y que, por ende, aún no dispone de estrategias terapéuticas
específicas. El objetivo de esta revisión está centrado en la aproximación
diagnóstica y terapéutica de la histiocitosis de células de Langerhans en adultos,
que permita facilitar su reconocimiento en etapas tempranas y mejorar el pronóstico
en las personas que la padecen.
REFERENCIAS (EN ESTE ARTÍCULO)
Tazi A. Adult pulmonary Langerhans' cell histiocytosis.Eur Respir J 2006;27:1272-1285. https://doi.org/10.1183/09031936.06.00024004.
Radzikowska E. Pulmonary Langerhans'cell histiocytosis in adults. Adv Respir Med2017;85:277-289. https://doi.org/10.5603/ARM.a2017.0046.
Lichtenstein L. Histiocytosis X; integration ofeosinophilic granuloma of bone, Letterer-Siwedisease, and Schüller-Christian disease as relatedmanifestations of a single nosologic entity.AMA Arch Pathol 1953;56:84-102.
Lampert F. Langerhans cell histiocytosis. Historicalperspectives. Hematol Oncol Clin NorthAm 1998;12:213-219. https://doi.org/10.1016/s0889-8588(05)70506-2.
Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans'cell histiocytosis. Thorax 2000;55:405-416. https://doi.org/10.1136/thorax.55.5.405.
Torre O, Elia D, Caminati A, Harari S.New insights in lymphangioleiomyomatosisand pulmonary Langerhans cell histiocytosis.Eur Respir Rev 2017;26. https://doi.org/10.1183/16000617.0042-2017.
Aricò M, Girschikofsky M, Généreau T, KlersyC, McClain K, Grois N, et al. Langerhanscell histiocytosis in adults. Report from the InternationalRegistry of the Histiocyte Society.Eur J Cancer 2003;39:2341-2348. https://doi.org/10.1016/s0959-8049(03)00672-5.
Weitzman S, Egeler RM. Langerhans cellhistiocytosis: update for the pediatrician.Curr Opin Pediatr 2008;20:23-29. https://doi.org/10.1097/MOP.0b013e3282f45ba4.
Vassallo R, Harari S, Tazi A. Current understandingand management of pulmonaryLangerhans cell histiocytosis. Thorax2017;72:937-945. https://doi.org/10.1136/thoraxjnl-2017-210125.
Emile JF, Abla O, Fraitag S, Horne A, HarocheJ, Donadieu J, et al. Revised classificationof histiocytoses and neoplasms of themacrophage-dendritic cell lineages. Blood2016;127:2672-2681. https://doi.org/10.1182/blood-2016-01-690636.
Colby TV, Lombard C. Histiocytosis X in thelung. Hum Pathol 1983;14:847-856. https://doi.org/10.1016/s0046-8177(83)80160-9.
Favara BE, Feller AC, Pauli M, Jaffe ES,Weiss LM, Arico M, et al. Contemporary classificationof histiocytic disorders. The WHOCommittee On Histiocytic/Reticulum Cell Proliferations.Reclassification Working Groupof the Histiocyte Society. Med Pediatr Oncol1997;29:157-166. https://doi.org/10.1002/(sici)1096-911x(199709)29:3<157::aidmpo1>3.0.co;2-c.
Delobbe A, Durieu J, Duhamel A, WallaertB. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X).Groupe d'Etude en Pathologie Interstitielle dela Société de Pathologie Thoracique du Nord.Eur Respir J 1996;9:2002-2006. https://doi.org/10.1183/09031936.96.09102002.
Vassallo R, Ryu JH, Schroeder DR, DeckerPA, Limper AH. Clinical outcomes of pulmonaryLangerhans'-cell histiocytosis in adults.N Engl J Med 2002;346:484-490. https://doi.org/10.1056/NEJMoa012087.
Aricò M, Egeler RM. Clinical aspects of Langerhanscell histiocytosis. Hematol OncolClin North Am 1998;12:247-258. https://doi.org/10.1016/s0889-8588(05)70508-6.
de Menthon M, Meignin V, Mahr A, TaziA. Histiocytose à cellules de Langerhans del’adulte. Press Medicale 2017;46:55-69. https://doi.org/10.1016/j.lpm.2016.09.015
Elia D, Torre O, Cassandro R, Caminati A,Harari S. Pulmonary Langerhans cell histiocytosis:a comprehensive analysis of 40 patientsand literature review. Eur J Intern Med2015;26:351-356. https://doi.org/10.1016/j.ejim.2015.04.001.
Juvet SC, Hwang D, Downey GP. Rare lungdiseases III: pulmonary Langerhans' cell histiocytosis.Can Respir J 2010;17:e55-62. https://doi.org/10.1155/2010/216240.
Schönfeld N, Dirks K, Costabel U,Loddenkemper R. A prospective clinical multicentrestudy on adult pulmonary Langerhans'cell histiocytosis. Sarcoidosis Vasc Diffuse LungDis 2012;29:132-138.
Murakami I, Matsushita M, Iwasaki T, KuwamotoS, Kato M, Nagata K, et al. Interleukin-1 loop model for pathogenesis of Langerhanscell histiocytosis. Cell Commun Signal2015;13:13. https://doi.org/10.1186/s12964-015-0092-z.
Haroche J, Cohen-Aubart F, Rollins BJ, DonadieuJ, Charlotte F, Idbaih A, et al. Histiocytoses:emerging neoplasia behind inflammation.Lancet Oncol 2017;18:e113-125. https://doi.org/10.1016/s1470-2045(17)30031-1.
Brown NA, Elenitoba-Johnson KSJ. Clinicalimplications of oncogenic mutations in pulmonaryLangerhans cell histiocytosis. CurrOpin Pulm Med 2018;24:281-286. https://doi.org/10.1097/mcp.0000000000000470.
Roden AC, Yi ES. Pulmonary Langerhanscell histiocytosis: An update from the pathologists'perspective. Arch Pathol Lab Med2016;140:230-240. https://doi.org/10.5858/arpa.2015-0246-RA.
Lorillon G, Tazi A. How I manage pulmonaryLangerhans cell histiocytosis.Eur Respir Rev 2017;26. https://doi.org/10.1183/16000617.0070-2017.
Radzikowska E. Update on pulmonary Langerhanscell histiocytosis. Front Med (Lausanne)2020;7:582581. https://doi.org/10.3389/fmed.2020.582581.
Fartoukh M, Humbert M, Capron F, Maître S,Parent F, Le Gall C, et al. Severe pulmonaryhypertension in histiocytosis X. Am J RespirCrit Care Med 2000;161:216-223. https://doi.org/10.1164/ajrccm.161.1.9807024.
Crausman RS, Jennings CA, Tuder RM, AckersonLM, Irvin CG, King TE, Jr. Pulmonaryhistiocytosis X: pulmonary function and exercisepathophysiology. Am J Respir Crit Care Med1996;153:426-435. https://doi.org/10.1164/ajrccm.153.1.8542154.
Harari S, Brenot F, Barberis M, Simmoneau G.Advanced pulmonary histiocytosis X is associatedwith severe pulmonary hypertension. Chest1997;111:1142-1144. https://doi.org/10.1378/chest.111.4.1142-a.
Knight RK. Haemoptysis in eosinophilic granuloma.Br J Dis Chest 1979;73:181-186.
Travis WD, Borok Z, Roum JH, Zhang J,Feuerstein I, Ferrans VJ, et al. PulmonaryLangerhans cell granulomatosis (histiocytosisX). A clinicopathologic study of 48 cases. AmJ Surg Pathol 1993;17:971-986. https://doi.org/10.1097/00000478-199310000-00002.
Friedman PJ, Liebow AA, Sokoloff J. Eosinophilicgranuloma of lung. Clinical aspectsof primary histiocytosis in the adult. Medicine(Baltimore) 1981;60:385-396.
Watanabe R, Tatsumi K, Hashimoto S, TamakoshiA, Kuriyama T. Clinico-epidemiologicalfeatures of pulmonary histiocytosis X.Intern Med 2001;40:998-1003. https://doi.org/10.2169/internalmedicine.40.998.
Abbott GF, Rosado-de Christenson ML,Franks TJ, Frazier AA, Galvin JR. From the archivesof the AFIP: pulmonary Langerhans cellhistiocytosis. Radiographics 2004;24:821-841.https://doi.org/10.1148/rg.243045005.
Grenier P, Valeyre D, Cluzel P, Brauner MW,Lenoir S, Chastang C. Chronic diffuse interstitiallung disease: diagnostic value of chestradiography and high-resolution CT. Radiology1991;179:123-132. https://doi.org/10.1148/radiology.179.1.2006262.
Wang FF, Liu YS, Zhu WB, Liu YD, Chen Y. PulmonaryLangerhans cell histiocytosis in adults:A case report. World J Clin Cases 2019;7:1892-1898. https://doi.org/10.12998/wjcc.v7.i14.1892.
Wei P, Lu HW, Jiang S, Fan LC, Li HP, Xu JF.Pulmonary langerhans cell histiocytosis: caseseries and literature review. Medicine (Baltimore)2014;93:e141. https://doi.org/10.1097/md.0000000000000141.
Lacronique J, Roth C, Battesti JP, Basset F,Chretien J. Chest radiological features of pulmonaryhistiocytosis X: a report based on 50adult cases. Thorax 1982;37:104-109. https://doi.org/10.1136/thx.37.2.104.
Obert J, Vercellino L, Van Der Gucht A, deMargerie-Mellon C, Bugnet E, Chevret S, etal. (18)F-fluorodeoxyglucose positron emissiontomography-computed tomography in themanagement of adult multisystem Langerhanscell histiocytosis. Eur J Nucl Med Mol Imaging2017;44:598-610. https://doi.org/10.1007/s00259-016-3521-3.
Albano D, Bosio G, Giubbini R, Bertagna F.Role of (18)F-FDG PET/CT in patients affectedby Langerhans cell histiocytosis. Jpn J Radiol2017;35:574-583. https://doi.org/10.1007/s11604-017-0668-1.
Hance AJ, Basset F, Saumon G, Danel C,Valeyre D, Battesti JP, et al. Smoking andinterstitial lung disease. The effect of cigarettesmoking on the incidence of pulmonaryhistiocytosis X and sarcoidosis. Ann NY Acad Sci 1986;465:643-656. https://doi.org/10.1111/j.1749-6632.1986.tb18541.x.
Auerswald U, Barth J, Magnussen H. Valueof CD-1-positive cells in bronchoalveolar lavagefluid for the diagnosis of pulmonary histiocytosisX. Lung 1991;169:305-309. https://doi.org/10.1007/bf02714167.
Casolaro MA, Bernaudin JF, Saltini C, FerransVJ, Crystal RG. Accumulation of Langerhans'cells on the epithelial surface of the lower respiratorytract in normal subjects in associationwith cigarette smoking. Am Rev Respir Dis1988;137:406-411. https://doi.org/10.1164/ajrccm/137.2.406.
Myers JL. Other diffuse lung diseases. In:Churg AM, Myers JL, Tazelaar HD, Wrigth JL,eds. Thurlbeck’s Pathology of the Lung. NewYork: Thieme; 2005. p. 601-673.
Popper HH. Die pulmonale Langerhans-zellhistiozytose.Der Pathologe 2015;36:451-457.https://doi.org/10.1007/s00292-015-0052-9.
Lieberman PH, Jones CR, Steinman RM,Erlandson RA, Smith J, Gee T, et al. Langerhanscell (eosinophilic) granulomatosis. A clinicopathologicstudy encompassing 50 years.Am J Surg Pathol 1996;20:519-552. https://doi.org/10.1097/00000478-199605000-00001.
Smetana K, Jr., Mericka O, Saeland S, HomolkaJ, Brabec J, Gabius HJ. Diagnostic relevanceof Langerin detection in cells from bronchoalveolarlavage of patients with pulmonaryLangerhans cell histiocytosis, sarcoidosis andidiopathic pulmonary fibrosis. Virchows Arch2004;444:171-174. https://doi.org/10.1007/s00428-003-0952-6.
Chaowalit N, Pellikka PA, Decker PA, AubryMC, Krowka MJ, Ryu JH, et al. Echocardiographicand clinical characteristics ofpulmonary hypertension complicating pulmonaryLangerhans cell histiocytosis. MayoClin Proc 2004;79:1269-1275. https://doi.org/10.4065/79.10.1269.
Etienne B, Bertocchi M, Gamondes JP, ThévenetF, Boudard C, Wiesendanger T, et al.Relapsing pulmonary Langerhans cell histiocytosisafter lung transplantation. Am J RespirCrit Care Med 1998;157:288-291. https://doi.org/10.1164/ajrccm.157.1.96-12107.
Dauriat G, Mal H, Thabut G, Mornex JF,Bertocchi M, Tronc F, et al. Lung transplantationfor pulmonary langerhans' cell histiocytosis:a multicenter analysis. Transplantation2006;81:746-750. https://doi.org/10.1097/01.tp.0000200304.64613.af.
Boehler A. Lung transplantation for cysticlung diseases: lymphangioleiomyomatosis,histiocytosis x, and sarcoidosis. Semin RespirCrit Care Med 2001;22:509-516. https://doi.org/10.1055/s-2001-18423.
Vassallo R, Ryu JH, Colby TV, Hartman T, LimperAH. Pulmonary Langerhans'-cell histiocytosis.N Engl J Med 2000;342:1969-1978. https://doi.org/10.1056/nejm200006293422607.
Lorillon G, Meignin V, Tazi A. [Adult pulmonaryLangerhans cell histiocytosis]. PresseMed 2017;46:70-78. https://doi.org/10.1016/j.lpm.2016.09.016.
DeMartino E, Go RS, Vassallo R. Langerhanscell histiocytosis and other histiocytic diseasesof the lung. Clin Chest Med 2016;37:421-430.https://doi.org/10.1016/j.ccm.2016.04.005.
Girschikofsky M, Arico M, Castillo D, Chu A, DoberauerC, Fichter J, et al. Management of adultpatients with Langerhans cell histiocytosis: recommendationsfrom an expert panel on behalf ofEuro-Histio-Net. Orphanet J Rare Dis 2013;8:72.https://doi.org/10.1186/1750-1172-8-72.
Adam Z, Szturz P, Vaníček J, Moulis M,Pour L, Krejčí M, et al. Cladribine (2-chlorodeoxyadenosine)in frontline chemotherapyfor adult Langerhans cell histiocytosis: A single-center study of seven cases. Acta Oncol2013;52:994-1001. https://doi.org/10.3109/0284186x.2012.716164.
Basset F, Corrin B, Spencer H, Lacronique J,Roth C, Soler P, et al. Pulmonary histiocytosisX. Am Rev Respir Dis 1978;118:811-820.https://doi.org/10.1164/arrd.1978.118.5.811.
Lombard CM, Medeiros LJ, Colby TV. Pulmonaryhistiocytosis X and carcinoma. Arch PatholLab Med 1987;111:339-341.
Tomashefski JF, Khiyami A, Kleinerman J.Neoplasms associated with pulmonary eosinophilicgranuloma. Arch Pathol Lab Med1991;115:499-506.
Tazi A, de Margerie C, Naccache JM, Fry S,Dominique S, Jouneau S, et al. The naturalhistory of adult pulmonary Langerhans cellhistiocytosis: a prospective multicentre study.Orphanet J Rare Dis 2015;10:30. https://doi.org/10.1186/s13023-015-0249-2.
Shaw B, Borchers M, Zander D, Gupta N. PulmonaryLangerhans cell histiocytosis. SeminRespir Crit Care Med 2020;41:269-279. https://doi.org/10.1055/s-0039-1700996.